NASDAQ:PHVS

Pharvaris (PHVS) Stock Forecast, Price & News

$20.87

+0.60 (+2.96%)

(As of 09/29/2023 ET)

Compare

Today's Range: $19.86
▼
$21.00
50-Day Range: $16.26
▼
$21.40
52-Week Range: $1.77
▼
$26.86

Volume: 32,619 shs
Average Volume: 43,407 shs
Market Capitalization: $664.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

Pharvaris MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 10.2% Upside
$23.00 Price Target
Short Interest: Healthy
0.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.88
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.46) to ($2.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

705th out of 972 stocks

Pharmaceutical Preparations Industry

328th out of 444 stocks

2.5

Analyst's Opinion

Consensus Rating
Pharvaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.00, Pharvaris has a forecasted upside of 10.2% from its current price of $20.87.
Amount of Analyst Coverage
Pharvaris has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.11% of the float of Pharvaris has been sold short.
Short Interest Ratio / Days to Cover
Pharvaris has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pharvaris has recently decreased by 22.05%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Pharvaris does not currently pay a dividend.
Dividend Growth
Pharvaris does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PHVS.

2.7

News and Social Media Coverage

News Sentiment
Pharvaris has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Pharvaris this week, compared to 1 article on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pharvaris insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Pharvaris are expected to grow in the coming year, from ($2.46) to ($2.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pharvaris is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pharvaris is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pharvaris has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

PHVS Price History

30 days | 90 days | 365 days | Advanced Chart

PHVS Stock News Headlines

September 29, 2023 | americanbankingnews.com

Pharvaris (NASDAQ:PHVS) Expected to Post Q3 2023 Earnings of ($0.62) Per Share

September 26, 2023 | msn.com

Wedbush Initiates Coverage of Pharvaris (PHVS) with Outperform Recommendation

October 1, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 26, 2023 | americanbankingnews.com

Pharvaris (NASDAQ:PHVS) Receives New Coverage from Analysts at Wedbush

September 25, 2023 | markets.businessinsider.com

Pharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% Upside

September 19, 2023 | finance.yahoo.com

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

September 14, 2023 | thestreet.com

Pharvaris N.V.

September 6, 2023 | finance.yahoo.com

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

October 1, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 6, 2023 | finance.yahoo.com

Pharvaris To Present at the 18th German Allergy Congress

August 31, 2023 | msn.com

Pharvaris (PHVS) Price Target Increased by 22.58% to 22.15

August 28, 2023 | finance.yahoo.com

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

August 23, 2023 | finance.yahoo.com

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

August 15, 2023 | msn.com

Morgan Stanley ups Pharvaris to overweight, citing HAE drug prospects

August 15, 2023 | markets.businessinsider.com

8 Analysts Have This to Say About Pharvaris

August 15, 2023 | msn.com

Morgan Stanley Upgrades Pharvaris (PHVS)

August 15, 2023 | cnbc.com

Morgan Stanley says this under-the-radar biotech stock can rally more than 80%

August 7, 2023 | finance.yahoo.com

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

July 27, 2023 | seekingalpha.com

Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development

July 21, 2023 | finance.yahoo.com

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

July 17, 2023 | markets.businessinsider.com

Analyst Expectations for Pharvaris's Future

July 10, 2023 | markets.businessinsider.com

Morgan Stanley Keeps Their Hold Rating on Pharvaris (PHVS)

July 6, 2023 | msn.com

Pharvaris (PHVS) Price Target Increased by 6.90% to 18.07

July 3, 2023 | finance.yahoo.com

Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 50% ownership, institutions own 18%

June 27, 2023 | finance.yahoo.com

Why Shares of Pharvaris N.V. Are Up Tuesday

June 26, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Pharvaris

June 26, 2023 | msn.com

Pharvaris stock climbs 13% after FDA lifts hold on HAE drug candidate

See More Headlines

Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

PHVS Company Calendar

Last Earnings: 8/07/2023
Today: 9/30/2023
Next Earnings (Estimated): 12/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PHVS
CUSIP: N/A
CIK: 1830487
Web: www.pharvaris.com
Phone: 31-71-203-6410
Fax: N/A
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $23.00
High Stock Price Forecast: $34.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +10.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-80,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -57.57%
Return on Assets: -51.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.89
Quick Ratio: 11.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.94 per share
Price / Book: 4.22

Miscellaneous

Outstanding Shares: 31,840,000
Free Float: N/A
Market Cap: $664.50 million
Optionable: Not Optionable
Beta: -3.83

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Berndt Axel Edvard Modig CPA (Age 64)
M.B.A., MBA, Co-Founder, CEO & Exec. Director
Comp: $534.85k

Dr. Jochen Knolle Ph.D. (Age 73)
Chief Scientific Officer & COO

Ms. Anna Nijdam M.Sc. (Age 42)
R.A., Head of Strategic Fin. & Principal Accounting Officer

Ms. Joan Schmidt J.D. (Age 59)
Chief Legal Officer

Dr. Peng Lu M.D. (Age 45)
Ph.D., Chief Medical Officer

Dr. Anne A. Lesage Ph.D. (Age 62)
Chief Early Devel. Officer

Dr. Morgan Conn Ph.D. (Age 54)
Chief Bus. Officer

Mr. Wim Souverijns Ph.D. (Age 52)
Chief Community Engagement & Commercial Officer

Maryann Cimino
Director of Corp. Relations

Ms. Annick Deschoolmeester (Age 50)
Chief HR Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PHVS Stock - Frequently Asked Questions

Should I buy or sell Pharvaris stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PHVS shares.
View PHVS analyst ratings or view top-rated stocks.
What is Pharvaris' stock price forecast for 2023?: 5 brokerages have issued 1 year target prices for Pharvaris' stock. Their PHVS share price forecasts range from $16.00 to $34.00. On average, they anticipate the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price.
View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts.
How have PHVS shares performed in 2023?: Pharvaris' stock was trading at $11.25 at the beginning of 2023. Since then, PHVS stock has increased by 85.5% and is now trading at $20.87.
View the best growth stocks for 2023 here.
Are investors shorting Pharvaris?: Pharvaris saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 15,200 shares, a decrease of 22.1% from the August 31st total of 19,500 shares. Based on an average daily volume of 68,900 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company's stock are short sold.
View Pharvaris' Short Interest.
When is Pharvaris' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, December 14th 2023.
View our PHVS earnings forecast.
How were Pharvaris' earnings last quarter?: Pharvaris (NASDAQ:PHVS) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.02.

When did Pharvaris IPO?: (PHVS) raised $126 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.
What is Pharvaris' stock symbol?: Pharvaris trades on the NASDAQ under the ticker symbol "PHVS."
How do I buy shares of Pharvaris?: Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pharvaris' stock price today?: One share of PHVS stock can currently be purchased for approximately $20.87.
How much money does Pharvaris make?: Pharvaris (NASDAQ:PHVS) has a market capitalization of $664.50 million. The company earns $-80,420,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.
How can I contact Pharvaris?: The official website for the company is www.pharvaris.com. The company can be reached via phone at 31-71-203-6410 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:PHVS) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial